Who Paid My Doc
Inomax
Drug Critical Care
NDC 64693-002-01
General payments
$6,773,864
Research payments
$2,050,532
Through program year 2025, $6,773,864 in general payments and $2,050,532 in research payments were reported against Inomax (Critical Care).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
14 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $1,150,689 | 154 |
| 2025 | Research | $300,083 | 3 |
| 2024 | General | $1,016,791 | 311 |
| 2024 | Research | $57,553 | 1 |
| 2023 | General | $722,629 | 321 |
| 2023 | Research | $104,594 | 6 |
| 2022 | General | $1,677,121 | 298 |
| 2022 | Research | $184,205 | 3 |
| 2021 | General | $448,418 | 133 |
| 2021 | Research | $192,429 | 4 |
| 2020 | General | $269,315 | 257 |
| 2020 | Research | $393,029 | 52 |
| 2019 | General | $1,488,900 | 957 |
| 2019 | Research | $818,640 | 96 |
Breakdown
The top 5 of 81 recipients; each share is of general payments naming this product in 2025.
The top 5 of 15 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 27 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
2,431 general · 165 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.